- BriaCell Therapeutics (BCTX, Financial) reports 100% resolution of lung metastasis in a patient with metastatic breast cancer.
- Complete tumor resolution observed in a heavily pre-treated patient at the lowest dose of Bria-OTS therapy.
- Findings indicate the potential efficacy of BriaCell's personalized immunotherapy, supporting further clinical development.
BriaCell Therapeutics Corp. (Nasdaq: BCTX), a clinical-stage biotechnology firm, has confirmed the complete resolution of lung metastasis in a 78-year-old patient with hormone receptor-positive (HR+) metastatic breast cancer. This was observed during their ongoing Phase 1/2a Bria-OTS study. The patient had previously undergone several unsuccessful treatments before participating in the study.
Enrolled on November 21, 2024, the patient received intradermal injections of Bria-OTS every two weeks for six weeks (total of four doses), followed by dosing every three weeks. Remarkably, the lung metastasis was resolved within two months, with disease stability confirmed at a four-month follow-up. The patient presented with extensive metastases to the bone, lymph nodes, and lung at study entry. Importantly, this response was achieved using the lowest dose level in the trial.
The Phase 1/2a dose escalation study (NCT06471673) is designed to assess Bria-OTS as both a monotherapy and in combination with an immune checkpoint inhibitor. This promising outcome highlights BriaCell's personalized off-the-shelf immunotherapy approach, which combines personalization benefits with manufacturing practicality in treating metastatic breast cancer.
While this advancement is promising, further studies are needed to validate these results across larger patient cohorts. This early success of Bria-OTS provides validation for the company's technology platform, which they hope will lead to broader clinical applications and possibly attract new investment opportunities.
